Compare Amylx Pharmaceuticals Inc (AMLX) vs Fox Corp Class B (FOX) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

FOX stock trades at $48.75, up 0.64% today, amid a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.41. The company's 2025 revenue surged to $16.3B, driving net income to $2.26B, while cash flow turned positive at $1.03B. Key developments include the $22B Roku acquisition, highlighting strategic moves in streaming, though leverage concerns have pressured the stock, which is down 25% over four weeks as of June 26, 2026 (Zacks Investment Research).

The outlook balances robust fundamentals against near-term headwinds. Valuation appears attractive with a P/E of 12.83 and EV/EBITDA of 8.19, but integration risks from the Roku deal and bearish technical trends pose challenges. Analyst consensus is mixed (42.86% Buy, 47.62% Hold), suggesting cautious optimism for long-term growth driven by streaming expansion and advertising recovery, though volatility may persist.